TouchIMMUNOLOGY had the pleasure of talking to Professor Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) around the efficacy and safety findings from the SELECTION study and its long term extension.
The abstract ‘Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study.‘ (OP04) was presented at the 16th Congress of ECCO, July 2-3 & 8-10, 2021, Virtual.
Questions
- What did the SELECTION study and its long term extension (LTE) teach us about the efficacy of filgotinib for the treatment of ulcerative colitis (UC)? (0:14)
- What safety concerns were associated with first generation JAK inhibitors, and how does filgotinib aim to overcome these? (2:21)
- What were the findings of your safety analysis of the SELECTION and SELECTION LTE data? (3:17)
- What will be the next steps for filgotinib in UC? (6:05)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist, Galapagos and Falk.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ECCO 2021 (Virtual).
